Related Experiment Video
Updated: Nov 26, 2025
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Exosome markers of LRRK2 kinase inhibition
Shijie Wang1, Kaela Kelly1, Jonathan M Brotchie2
1Department of Pharmacology and Cancer Biology, Duke Center for Neurodegeneration Research, Duke University, Durham, NC, USA.
Abstract:
Hyper-activated LRRK2 is linked to Parkinson's disease susceptibility and progression. Quantitative measures of LRRK2 inhibition, especially in the brain, maybe critical in the development of successful LRRK2-targeting therapeutics. In this study, two different brain-penetrant and selective LRRK2 small-molecule kinase inhibitors (PFE-360 and MLi2) were orally administered to groups of cynomolgus macaques. Proposed pharmacodynamic markers in exosomes from urine and cerebrospinal fluid (CSF) were compared to established markers in peripheral blood mononuclear cells (PBMCs). LRRK2 kinase inhibition led to reductions in exosome-LRRK2 protein and the LRRK2-substrate pT73-Rab10 in urine, as well as reduced exosome-LRRK2 and autophosphorylated pS1292-LRRK2 protein in CSF. We propose orthogonal markers for LRRK2 inhibition in urine and CSF can be used in combination with blood markers to non-invasively monitor the potency of LRRK2-targeting therapeutics.
Insights
Parkinson's disease drug development requires measuring LRRK2 inhibition. New urine and cerebrospinal fluid (CSF) exosome markers, alongside blood markers, can non-invasively monitor LRRK2-targeting therapeutics.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Hyper-activated Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in Parkinson's disease (PD) pathogenesis.
- Accurate measurement of LRRK2 inhibition in the brain is crucial for developing effective PD therapeutics.
- Current methods for monitoring drug efficacy may not fully capture central nervous system target engagement.
Purpose of the Study:
- To evaluate novel, non-invasive pharmacodynamic markers of LRRK2 kinase inhibition in urine and cerebrospinal fluid (CSF) exosomes.
- To compare these novel markers with established markers in peripheral blood mononuclear cells (PBMCs).
- To assess the brain penetrance and inhibitory effects of two selective LRRK2 inhibitors in a non-human primate model.
Main Methods:
- Oral administration of two brain-penetrant LRRK2 inhibitors (PFE-360 and MLi2) to cynomolgus macaques.
- Collection and analysis of urine, CSF, and blood samples.
- Quantification of exosome-associated LRRK2 protein, pT73-Rab10, and pS1292-LRRK2 in collected biofluids and PBMCs.
Main Results:
- LRRK2 inhibition significantly reduced exosome-LRRK2 and pT73-Rab10 levels in urine.
- Reduced exosome-LRRK2 and autophosphorylated pS1292-LRRK2 were observed in CSF following LRRK2 inhibition.
- Exosome markers in urine and CSF demonstrated sensitivity to LRRK2 kinase inhibition, correlating with blood marker changes.
Conclusions:
- Urinary and CSF exosome markers serve as reliable, non-invasive indicators of LRRK2 target engagement.
- These novel markers can complement traditional blood-based biomarkers for monitoring LRRK2 inhibitor potency.
- The findings support the use of these orthogonal markers in clinical trials for Parkinson's disease therapeutics targeting LRRK2.
